504 related articles for article (PubMed ID: 33921360)
61. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
62. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
Drugs; 2024 Jun; 84(6):661-684. PubMed ID: 38849701
[TBL] [Abstract][Full Text] [Related]
63. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
64. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
65. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
66. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
67. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
68. Targeting of eosinophils in asthma.
Molfino NA
Expert Opin Biol Ther; 2012 Jul; 12(7):807-9. PubMed ID: 22500988
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
70. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
[TBL] [Abstract][Full Text] [Related]
71. Benralizumab in Real Life.
Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
[No Abstract] [Full Text] [Related]
72. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
73. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
74. Biologics for oral corticosteroid-dependent asthma.
Yılmaz İ
Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
[No Abstract] [Full Text] [Related]
75. Benralizumab for the treatment of asthma.
Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
[TBL] [Abstract][Full Text] [Related]
76. Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma.
Rial MJ; Cañas JA; Rodrigo-Muñoz JM; Valverde-Monge M; Sastre B; Sastre J; Del Pozo V
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808110
[TBL] [Abstract][Full Text] [Related]
77. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
[TBL] [Abstract][Full Text] [Related]
78. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
[TBL] [Abstract][Full Text] [Related]
79. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
80. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
